Loading...
HGEN.Q logo

Humanigen, Inc.OTCPK:HGEN.Q Stock Report

Market Cap US$119.0
Share Price
n/a
My Fair Value
n/a
1Y-100.0%
7D-99.5%
1D
Portfolio Value
​
View

Humanigen, Inc.

OTCPK:HGEN.Q Stock Report

Market Cap: US$119.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Humanigen (HGEN.Q) Stock Overview

A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. More details

HGEN.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Highly volatile share price over the past 3 months

Revenue has declined by 59% over the past year

Does not have a meaningful market cap ($119)

+ 2 more risks

HGEN.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Humanigen, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Humanigen
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.21
52 Week LowUS$0.000001
Beta-1.34
1 Month Change0%
3 Month Change0%
1 Year Change-100.00%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 12

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Humanigen press release (NASDAQ:HGEN): Q2 GAAP EPS of -$0.43 misses by $0.11. Revenue of $1.04M (flat Y/Y) beats by $0.69M. As of June 30, 2022, the company had cash and cash equivalents of approximately $47.0 million. Shares +1.93%.
Seeking Alpha • Jul 13

Humanigen plunges 57% as trial for COVID-19 therapy fails

The shares of clinical-stage biotech Humanigen, Inc. (NASDAQ:HGEN) dropped ~57% in the pre-market Wednesday after the company announced that its experimental antibody Lenzilumab failed in a trial involving hospitalized COVID-19 patients. ACTIV-5/BET-B trial was a partnership between Humanigen (HGEN) and the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. According to preliminary topline data, the trial did not show statistical significance on the primary endpoint. However, the results indicated a non-significant trend of a decline in mortality in the overall patient population [HR 0.72]. The researchers found no new safety events related to lenzilumab. “…..while the ACTIV-5/BET-B study showed signs of a clinical effect, the benefit demonstrated was not able to confirm the positive results we saw in our Phase 3 LIVE-AIR study,” Chief Executive Cameron Durrant noted. Early this month, Humanigen (HGEN) shares gained after the company announced the peer-reviewed publication of data supporting lenzilumab.
Seeking Alpha • Jul 06

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Clinical-stage biotech Humanigen (NASDAQ:HGEN) rose more than 10% on Wednesday after the company announced a peer-reviewed publication of data supporting its investigational COVID-19 therapy lenzilumab. The publication in the medical journal Thorax was based on the data from the company’s Phase 3 LIVE-AIR study.  The data illustrate the function of C-reactive protein (CRP) in identifying patients who will likely receive the greatest benefit of lenzilumab. The LIVE-AIR study involving hospitalized COVID-19 patients point to a strong relationship between CRP and outcomes with lenzilumab treatment. Those who received lenzilumab with a baseline CRP of less than 150 mg/L were found to have the greatest clinical benefit, the company said, noting a 62% reduction in the relative risk of invasive mechanical ventilation and death compared to those who received the placebo. Read: Last month, Humanigen (HGEN) partnered with PCI Pharma Services to introduce lenzilumab in the U.K. market.
Analysis Article • Oct 30

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Jul 14

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • May 05

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

Today we will run through one way of estimating the intrinsic value of Humanigen, Inc. ( NASDAQ:HGEN ) by estimating...
Analysis Article • Mar 31

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

With the business potentially at an important milestone, we thought we'd take a closer look at Humanigen, Inc.'s...
Analysis Article • Feb 26

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

If you want to know who really controls Humanigen, Inc. ( NASDAQ:HGEN ), then you'll have to look at the makeup of its...
Analysis Article • Jan 04

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example...

Shareholder Returns

HGEN.QUS BiotechsUS Market
7D-99.5%1.2%1.1%
1Y-100.0%34.6%28.7%

Return vs Industry: HGEN.Q underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: HGEN.Q underperformed the US Market which returned 22% over the past year.

Price Volatility

Is HGEN.Q's price volatile compared to industry and market?
HGEN.Q volatility
HGEN.Q Average Weekly Movement102,515.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: HGEN.Q's share price has been volatile over the past 3 months.

Volatility Over Time: HGEN.Q's weekly volatility has increased from 50618% to 102515% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20006Cameron Durrantwww.humanigen.com

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.

Humanigen, Inc. Fundamentals Summary

How do Humanigen's earnings and revenue compare to its market cap?
HGEN.Q fundamental statistics
Market capUS$119.00
Earnings (TTM)-US$53.63m
Revenue (TTM)US$1.70m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is HGEN.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HGEN.Q income statement (TTM)
RevenueUS$1.70m
Cost of RevenueUS$38.73m
Gross Profit-US$37.03m
Other ExpensesUS$16.61m
Earnings-US$53.63m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin-2,179.40%
Net Profit Margin-3,156.80%
Debt/Equity Ratio0%

How did HGEN.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/15 03:05
End of Day Share Price 2024/07/15 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Humanigen, Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Michael KingCitizens JMP Securities, LLC
Joseph PantginisH.C. Wainwright & Co.